The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

BACKGROUND: Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset of patients benefits from anti-PD-1/PD-L1 therapies. As a negative regulator...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Yi, Ming, Zhang, Jing, Li, Anping, Niu, Mengke, Yan, Yongxiang, Jiao, Ying, Luo, Suxia, Zhou, Pengfei, Wu, Kongming
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2021
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885589/
https://ncbi.nlm.nih.gov/pubmed/33593403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01045-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker